跳至主要内容
临床试验/NCT02285140
NCT02285140终止不适用

Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial

Hamilton Health Sciences Corporation4 个研究点 分布在 1 个国家目标入组 5,989 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
5,989
试验地点
4
主要终点
Proportion of patients receiving antibiotics according to study protocol

研究概览

简要总结

There is clinical equipoise about the question of whether antibiotic prophylaxis should be given for a short period or an extended period of time as reflected by inconsistencies in major guidelines, current practices at Canadian centers, and as concluded in the three systematic reviews. There also is clinical equipoise on whether the addition of vancomycin to routine cefazolin prophylaxis can further reduce s-SSI rates. A short duration of combined antimicrobial prophylaxis can reduce side effects of exposure to antimicrobials such as infections with C. difficile or emergence of resistance, but may also reduce the incidence of s-SSIs. The objective of the eventual full scale study is to determine whether adding vancomycin to cefazolin can reduce SSIs as well as whether short-term prophylaxis is as effective as long-term prophylaxis. The rationale to conduct the proposed pilot study is to assess the feasibility to conduct this factorial cluster randomized cross-over trial, the adherence to the study protocol at each pilot site, the length of time to fill out the case report forms, and to get reliable estimates of event rates for sample size calculation for the main study

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All adult patients (≥18 years of age) undergoing open-heart surgery (sternotomy, including minimally-invasive surgical techniques).

排除标准

  • Patients on antibiotics at the time of surgery.
  • Previous enrollment in this trial.
  • Known MRSA carriers. Beta-lactam allergy (IgE-mediated) precluding the use of cefazolin
  • Participant in another study that may interfere with this trial.

研究组 & 干预措施

Cefazolin monotherapy, short course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered

干预措施: Cefazolin (Drug)

Cefazolin monotherapy, long course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).

干预措施: Cefazolin (Drug)

Combination therapy, short course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.

干预措施: Cefazolin (Drug)

Combination therapy, short course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.

干预措施: Vancomycin (Drug)

Combination therapy, long course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)

干预措施: Cefazolin (Drug)

Combination therapy, long course

Experimental

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)

干预措施: Vancomycin (Drug)

结局指标

主要结局

Proportion of patients receiving antibiotics according to study protocol

时间窗: 3 months post-surgery

Co-Primary outcome of pilot study

Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%

时间窗: 3 months post-surgery

Co-Primary outcome of pilot study

Agreement of blinded outcome assessment based on information from the case report form

时间窗: 3 months post-surgery

Co-Primary outcome of pilot study

次要结局

  • Deep incisional and organ/space sternal surgical site infection (NHSN/CDC)(3 months post-surgery)
  • Clostridium difficile infection(3 months post-surgery)
  • All types of sternal surgical site infection (superficial, deep, organ; NHSN/CDC)(3 months post-surgery)
  • Mortality(3 months post-surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dominik Mertz

Assistant Professor, Medical Director Infection Prevention and Control

Hamilton Health Sciences Corporation

研究点 (4)

Loading locations...

相似试验